EquitiesIndia.com

Healthcare · Drug Manufacturers - Specialty & Generic

Cohance Lifesciences Ltd.

COHANCE

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Key metrics

Market Cap

₹14,471 cr

P/E Ratio

74.68x

P/B Ratio

8.53x

ROE

15.79%

ROCE

17.99%

Debt / Equity

0.16x

Net Margin

22.85%

Dividend Yield

EPS

₹10.45

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 63.97%FII: 24.66%Public: 11.37%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Cohance Lifesciences Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.